Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Earnings for Immuneering Corporation (IMRX)
Earnings in 2023 (TTM): $-53,471,622
According to Immuneering Corporation's latest financial reports the company's current earnings (TTM) are $-53,471,622. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Immuneering Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-53,471,622 | $-53,471,622 |
| 2022 | $-50,513,568 | $-49,281,797 |
| 2021 | $-33,843,233 | $-33,535,748 |
| 2020 | $-17,039,898 | $-17,039,898 |
| 2019 | $-7,709,448 | $-8,060,750 |